GILD Stock Analysis: Gilead Sciences | NASDAQ
Drug Manufacturers - General | NASDAQ, USA | Market Cap: 153.756m USD | 12M Return: 18.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.17B
EPS Trend: 51.3%
Qual. Beats: 0
Rev. Trend: 96.9%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
Gilead Sciences is a U.S.-headquartered biopharmaceutical company founded in 1987 and based in Foster City, California. Listed on NASDAQ since 1992, it operates in the biotechnology sub-industry of health care, discovering, developing, and commercializing medicines primarily in areas of unmet medical need across the United States, Europe, and other international markets.
The companys commercial portfolio spans several major therapeutic areas. Its HIV franchise includes Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, and Yeztugo for the treatment of HIV-1 infection. For liver diseases, Gilead markets Epclusa and Vemlidy (hepatitis B and C) and Livdelzi (primary biliary cholangitis). In oncology, it offers Tecartus and Yescarta as CAR T-cell therapies, along with Trodelvy for certain cancers. Additional products include AmBisome for serious invasive fungal infections and Veklury for COVID-19. Biopharmaceutical companies like Gilead typically generate revenue through prescription drug sales protected by patents and regulatory exclusivity periods.
Gilead supplements its internal pipeline with extensive external partnerships, holding collaboration or licensing agreements with entities including Arcus Biosciences, Merck Sharp & Dohme Corp., Janssen Sciences Ireland, Everest Medicines, Assembly Biosciences, Merus N.V., Terray Therapeutics, and LEO Pharma. These agreements cover areas such as trispecific antibodies, small molecule therapies, and the oral STAT6 program. Partnership-driven R&D is a common feature of the biotech sector, where licensing and collaboration deals help spread development risk and broaden pipeline access.
- Biktarvy patent expiry threatens core HIV franchise revenue
- Lenacapavir PrEP approval accelerates HIV growth runway
- Yescarta CAR-T sales pressured by bispecific antibody competition
| Net Income: 9.22b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.18 > 0.02 and ΔFCF/TA 0.73 > 1.0 |
| NWC/Revenue: 30.82% < 20% (prev 15.86%; Δ 14.96% < -1%) |
| CFO/TA 0.19 > 3% & CFO 10.8b > Net Income 9.22b |
| Net Debt (12.4b) to EBITDA (14.5b): 0.85 < 3 |
| Current Ratio: 1.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.25b) vs 12m ago -0.40% < -2% |
| Gross Margin: 79.35% > 18% (prev 78.29%; Δ 1.07% > 0.5%) |
| Asset Turnover: 52.76% > 50% (prev 50.92%; Δ 1.84% > 0%) |
| Interest Coverage Ratio: 11.67 > 6 (EBIT TTM 11.7b / Interest Expense TTM 1.00b) |
| A: 0.16 (Total Current Assets 18.6b - Total Current Liabilities 9.48b) / Total Assets 56.3b |
| B: 0.25 (Retained Earnings 14.1b / Total Assets 56.3b) |
| C: 0.21 (EBIT TTM 11.7b / Avg Total Assets 56.4b) |
| D: 0.72 (Book Value of Equity 23.5b / Total Liabilities 32.8b) |
| Altman-Z'' = 4.04 = AA |
| DSRI: 1.04 (Receivables 4.74b/4.39b, Revenue 29.7b/28.7b) |
| GMI: 0.99 (GM 78.29% / 79.35%) |
| AQI: 0.94 (AQ_t 0.57 / AQ_t-1 0.60) |
| SGI: 1.03 (Revenue 29.7b / 28.7b) |
| TATA: -0.03 (NI 9.22b - CFO 10.8b) / TA 56.3b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of June 30, 2026, the stock is trading at USD 126.33 with a total of 6,646,508 shares traded. Over the past week, the price has changed by +3.33%, over one month by -5.51%, over three months by -5.59% and over the past year by +18.35%.
Current recommended Stop Loss: 121.70 (which is 3.7% or 1.3 ATR below the current price).
Gilead Sciences has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy GILD.
- StrongBuy: 15
- Buy: 4
- Hold: 11
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 157.6 | 24.7% |
P/E Trailing = 16.8261
P/E Forward = 15.2207
P/S = 5.1707
P/B = 6.5386
P/EG = 2.1441
Revenue TTM = 29.7b USD
EBIT TTM = 11.7b USD
EBITDA TTM = 14.5b USD
Long Term Debt = 20.9b USD (from longTermDebt, last quarter)
Short Term Debt = 1.31b USD (from shortTermDebt, last quarter)
Debt = 22.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.4b USD (calculated: Debt 22.2b - CCE 9.82b)
Enterprise Value = 166b USD (154b + Debt 22.2b - CCE 9.82b)
Interest Coverage Ratio = 11.67 (Ebit TTM 11.7b / Interest Expense TTM 1.00b)
EV/FCF = 16.24x (Enterprise Value 166b / FCF TTM 10.2b)
FCF Yield = 6.16% (FCF TTM 10.2b / Enterprise Value 166b)
FCF Margin = 34.40% (FCF TTM 10.2b / Revenue TTM 29.7b)
Net Margin = 30.99% (Net Income TTM 9.22b / Revenue TTM 29.7b)
Gross Margin = 79.35% ((Revenue TTM 29.7b - Cost of Revenue TTM 6.14b) / Revenue TTM)
Gross Margin QoQ = 79.24% (prev 79.51%)
Tobins Q-Ratio = 2.95 (Enterprise Value 166b / Total Assets 56.3b)
Interest Expense / Debt = 4.53% (Interest Expense 1.00b / Debt 22.2b)
Taxrate = 14.08% (1.51b / 10.7b)
NOPAT = 10.1b (EBIT 11.7b * (1 - 14.08%))
Current Ratio = 1.97 (Total Current Assets 18.6b / Total Current Liabilities 9.48b)
Debt / Equity = 0.94 (Debt 22.2b / totalStockholderEquity, last quarter 23.5b)
Debt / EBITDA = 0.85 (Net Debt 12.4b / EBITDA 14.5b)
Debt / FCF = 1.21 (Net Debt 12.4b / FCF TTM 10.2b)
Total Stockholder Equity = 21.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.35% (Net Income 9.22b / Total Assets 56.3b)
RoE = 42.16% (Net Income TTM 9.22b / Total Stockholder Equity 21.9b)
RoCE = 27.47% (EBIT 11.7b / Capital Employed (Equity 21.9b + L.T.Debt 20.9b))
RoIC = 21.62% (NOPAT 10.1b / Invested Capital 46.6b)
WACC = 6.57% (E(154b)/V(176b) * Re(6.96%) + D(22.2b)/V(176b) * Rd(4.53%) * (1-Tc(0.14)))
Discount Rate = 6.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 2.33 | Cagr: -0.07%
[DCF] Terminal Value 75.94% ; FCFF base≈10.1b ; Y1≈10.4b ; Y5≈11.8b
[DCF] Fair Price = 136.8 (EV 182b - Net Debt 12.4b = Equity 170b / Shares 1.24b; r=8.35% [WACC [floored]]; 5y FCF grow 3.91% → 2.50% )
EPS Correlation: 51.29 | EPS CAGR: 16.66% | SUE: 0.48 | # QB: 0
Revenue Correlation: 96.88 | Revenue CAGR: 3.43% | SUE: 0.17 | # QB: 0
EPS next Quarter (2026-09-30): EPS=2.08 | Chg30d=+16.93% | Revisions=-26% | Analysts=19
EPS current Year (2026-12-31): EPS=-0.79 | Chg30d=+0.72% | Revisions=-85% | GrowthEPS=-109.7% | GrowthRev=+3.5%
EPS next Year (2027-12-31): EPS=9.68 | Chg30d=+0.95% | Revisions=-15% | GrowthEPS=+1326.1% | GrowthRev=+6.4%
[Analyst] Revisions Ratio: -85%